Fukuyama Congenital Muscular Dystrophy (FCMD) is a rare inherited condition that primarily affects muscle development and brain structure. First described in Japan, FCMD is most commonly seen in individuals of Japanese ancestry, although cases have been reported worldwide. As a form of congenital muscular dystrophy, symptoms are present from birth or early infancy and can have a significant impact on a child’s development.
What Causes FCMD?
FCMD is caused by changes (mutations) in the FKTN gene. This gene plays a critical role in the production of a protein called fukutin, which is involved in the proper glycosylation of alpha-dystroglycan – a protein essential for maintaining the structural integrity of muscle cells and supporting normal brain development.
When the FKTN gene is not functioning correctly, alpha-dystroglycan cannot perform its role effectively. This leads to muscle weakness and abnormalities in the brain, particularly in areas responsible for movement and coordination.
FCMD is inherited in an autosomal recessive pattern. This means that a child must inherit two non-working copies of the FKTN gene, one from each parent, to be affected. Parents who carry one altered copy are typically healthy but have a 25% chance with each pregnancy of having an affected child.
Signs and Symptoms
Children with FCMD usually present with symptoms early in life. One of the first signs is hypotonia, or low muscle tone, often described as “floppiness” in infancy. As the child grows, muscle weakness becomes more apparent, particularly in the proximal muscles (those closest to the centre of the body).
Developmental delays are common, especially in motor milestones such as sitting, standing, and walking. Many children with FCMD may never achieve independent walking.
In addition to muscle involvement, FCMD is associated with brain abnormalities, including a condition known as cobblestone lissencephaly. This refers to an irregular brain surface that can affect cognitive development. As a result, intellectual disability is often present, ranging from mild to severe.
Other possible features include:
- Seizures
- Vision problems
- Feeding difficulties
- Joint contractures
Diagnosis
Diagnosis of FCMD typically involves a combination of clinical assessment, imaging studies, and genetic testing. Brain MRI findings can reveal characteristic structural differences, while genetic testing can confirm changes in the FKTN gene.
In some cases, elevated levels of creatine kinase (CK) in the blood may also support the diagnosis, as this enzyme leaks from damaged muscle cells.
Management and Care
There is currently no cure for FCMD, so management focuses on supportive care and improving quality of life. A multidisciplinary approach is essential and may include neurologists, physiotherapists, occupational therapists, speech pathologists, and genetic counsellors.
Interventions may involve:
- Physical therapy to maintain mobility and prevent contractures
- Nutritional support for feeding difficulties
- Anti-seizure medications if seizures are present
- Educational support tailored to the child’s needs
Regular monitoring is important to address complications early and adjust care as needed.
The Role of Genetic Counselling
Genetic counselling plays a key role in supporting families affected by FCMD. It helps individuals understand the genetic basis of the condition, the inheritance pattern, and the likelihood of recurrence in future pregnancies. Carrier testing and reproductive options, including prenatal testing, may be discussed where appropriate.
At Rosalind Genetics, we recognise that receiving a diagnosis like FCMD can be overwhelming. Our goal is to provide clear, compassionate guidance to help families make informed decisions and feel supported every step of the way.
Looking Ahead
While FCMD remains a serious condition, advances in genetic research are improving our understanding of how it develops. Ongoing studies into gene function and potential therapies offer hope for future treatment options.
If you have concerns about muscle weakness, developmental delay, or a family history of genetic conditions, seeking expert advice can make a meaningful difference. Early diagnosis and coordinated care are key to achieving the best possible outcomes for affected individuals and their families.
